首页 正文

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer

{{output}}
As systemic therapies for non-small cell lung cancer (NSCLC) have become more effective, interest in their use for improving long-term surgical outcomes has rapidly increased. Imperfect as it is, stage remains the primary means for identifying patients who mig... ...